Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Starting Wednesday, people on Medicare will be able to get weight loss drugs, including Wegovy and Zepbound, for $50 a month
Our patients report not just weight loss, but transformative experiences: Increased energy levels Improved metabolic health Enhanced self-confidence Better sleep patterns Reduced risk of weight-related health complications Your Investment in Yourself Weight loss treatments are an investment in your health, your future, and your quality of life
Evaluating rezatapopt*, a first-in-class p53 reactivator, as a treatment for TP53 Y220Cmutant locally advanced and metastatic solid tumours The experts discuss: TP53 Y220C mutation and rationale for targeted therapy Study overview and practice implications, spotlighting ovarian cancer Testing strategies for early and accurate patient identification Video in this post *Rezatapopt is an investigational agent which is not approved by a regulatory agency This programme has been sponsored by PMV Pharma #MedicalEducation #Oncology Update from AACRNCIEORTC 2025: PYNNACLE Phase 2 evaluating rezatapopt in TP53 Y220Cmutant solid tumours To view or add a comment, sign in 26,256 followers
This fresh evidence on cardiovascular outcomes in diabetes is changing practice guidelines and redefining what optimal treatment means for patients and clinicians
poor nutrition or vegan diet) Transcobalamin II deficiency It is also used as part of the vitamin B12 absorption test (Schilling test)
